WI-211094 / WhanIn - LARVOL DELTA

Characterization of a novel small-molecule LRRK2 inhibitor WI-211094 as a potential therapeutic agent for Parkinson's disease (Neuroscience 2022) - "In mice, WI-211094 was well tolerated up to 1000 mg/kg once daily for 2 weeks without histopathological alterations in tissues, especially lung adverse effects. Taken together, we suggest that WI-211094, a novel, advanced, and generally safe LRRK2 inhibitor, might be a potential therapeutic candidate for both iPD patients and familial PD patients with LRRK2 mutation."

CNS Disorders • Parkinson's Disease • TNFA